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Preeclampsia (PE) complicates ∼5% of human pregnancies and is
one of the leading causes of pregnancy-related maternal deaths.
The only definitive treatment, induced delivery, invariably results
in prematurity, and in severe early-onset cases may lead to fetal
death. Many currently available antihypertensive drugs are tera-
togenic and therefore precluded from use. Nonteratogenic antihy-
pertensives help control maternal blood pressure in PE, but results
in preventing preterm delivery and correcting fetal growth restric-
tion (FGR) that also occurs in PE have been disappointing. Here we
show that dietary nicotinamide, a nonteratogenic amide of vita-
min B3, improves the maternal condition, prolongs pregnancies,
and prevents FGR in two contrasting mouse models of PE. The first
is caused by endotheliosis due to excess levels in the mothers of a
soluble form of the receptor for vascular endothelial growth factor
(VEGF), which binds to and inactivates VEGF. The second is caused
by genetic absence of Ankiryn-repeat-and-SOCS-box–containing-
protein 4, a factor that contributes to the differentiation of tropho-
blast stem cells into the giant trophoblast cells necessary for embryo
implantation in mice; its absence leads to impaired placental devel-
opment. In both models, fetal production of ATP is impaired and
FGR is observed. We show here that nicotinamide decreases blood
pressure and endotheliosis in the mothers, probably by inhibiting
ADP ribosyl cyclase (ADPRC), and prevents FGR, probably by normal-
izing fetal ATP synthesis via the nucleotide salvage pathway. Be-
cause nicotinamide benefits both dams and pups, it merits evaluation
for preventing or treating PE in humans.
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The maternal hypertension and proteinuria characterizingpreeclampsia (PE) are primarily consequences of an imbal-
ance between proangiogenic growth factors that promote vas-
cular well-being (such as VEGF), and antiangiogenic factors that
sequester the growth factors (such as the soluble form of VEGF
receptor-1, now referred to as sFLT1) (1). Both the hypertension
and the proteinuria of PE are caused by abnormally high amounts
of antiangiogenic factors derived from the placenta. Fetal growth
restriction (FGR), an additional feature of PE, is a consequence of
reduced placental blood flow resulting from damage to the pla-
cental vasculature caused by antiangiogenic factors and/or to im-
paired development of the placenta. Endothelin-1 (EDN1) is the
most powerful naturally occurring prohypertensive peptide, and
antagonists of the endothelin type A receptor (EDNRA) greatly
ameliorate the PE-like condition that develops in the kidneys of
rodents with excess sFLT1 (2, 3). Unfortunately, these antagonists
are teratogenic (4) and consequently unacceptable for use in
treating PE.
Nicotinamide is a potential nonteratogenic alternative because
it relaxes blood vessels constricted with EDN1 (5) and because it
has been extensively tested at high oral doses in men and (non-
pregnant) women and found safe (6).
Results and Discussion
Nicotinamide Ameliorates the Hypertension, Albuminuria, and Renal
Abnormalities in PE Caused by Increased Maternal Production of
Flt1(1-3). To explore the potential of nicotinamide for treating PE,
we first evaluated its effects on the PE-like condition induced in
nonpregnant female inbred strain C57BL/6J mice by adminis-
trating 109 plaque forming units (pfu) of a recombinant adenovi-
rus, rAdV Flt1(1-3), that infects the liver and causes production
of Flt1(1-3) and increases its concentration in the plasma (7).
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[Flt(1-3) is a synthetic protein that includes a signal sequence,
the first 328 amino acids of FLT1, and six copies of a His tag.]
These experiments showed that 500 mg/kg per day of oral nic-
otinamide has significant beneficial effects on the hypertension,
albuminuria, damage to the endothelium of the renal glomerular
capillaries, and glomerular mesangial expansion caused by the
Flt1(1-3) (Fig. S1). [The amount of nicotinamide used in these
and all of our other experiments (500 mg/kg per day) is equiv-
alent to 2.5 g/d in a 60-kg human, when corrected for body
surface area (8), and consequently does not exceed doses (3–9 g
daily) that are commonly used (9, 10).]
We next tested the effects of nicotinamide in pregnant C57BL/
6J mice receiving 109 pfu of the Flt1(1-3) virus at 7.5 d post-
coitum (dpc). However, this led to miscarriages by 10.5 dpc.
Accordingly, the experiment was repeated using out-bred mice
(ICR) and less virus. The results show that nicotinamide pre-
vents the Flt1(1-3)–induced increase in telemetrically measured
systolic blood pressure (SBP; Fig. 1A) and reduces the urinary
excretion of albumin [albumin/creatinine ratio (ACR)] to a level
indistinguishable from control pregnant mice not receiving nic-
otinamide (Fig. 1B).
Widespread endothelial damage is an invariable finding in
PE; indeed, renal glomerular endotheliosis is the most char-
acteristic morphologic lesion of the human condition (11).
The same type of endotheliosis develops in pregnant mice
receiving the Flt1(1-3) virus, and this is ameliorated by nico-
tinamide. Thus, the glomerular open capillary area (an in-
dicator of the status of the capillary endothelium) was decreased
to ∼60% normal in the pregnant mice receiving the Flt1(1-3)
virus alone, but was improved to ∼80% normal if the mice also
received nicotinamide (Fig. 1C). Likewise in the same samples,
the marked increase in periodic acid-Schiff (PAS) stain-pos-
itive area (an indicator of mesangial expansion) was prevented
by nicotinamide (Fig. 1D). Representative light and electron
micrographs of the renal glomeruli directly illustrate the
endotheliosis and mesangial expansion caused by the virus and
confirm that nicotinamide substantially reduces their severity
(Fig. 1 E and F). These beneficial effects were seen despite
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Fig. 1. Nicotinamide (Nam) ameliorates the high BP, urinary albumin ex-
cretion, endotheliosis, and mesangial expansion induced in pregnant mice
by Flt1(1-3). (A) SBPs of pregnant outbred ICR mice before and after receiving
6 × 108 pfu rAdV Flt1(1-3) at 14.5 dpc and given or not given Nam daily by
gavage (500 mg/kg per day) starting at 12.5 dpc. Nam prevented the Flt1(1-3)
induced increase in SBP. Data are average of 3 d [9.5–11.5.dpc for previrus and
16.5–18.5 dpc after rAdV Flt1(1-3)]. (B) ACRs of urine samples at 17.5 dpc from
pregnant mice that received 6 × 108 pfu rAdV GFP alone (Control), rAdV GFP
plus Nam (Nam), Flt1(1-3) virus alone [Flt1(1-3)], or Flt1(1-3) virus plus Nam
[Flt1(1-3)+Nam]. Nam prevented the Flt1(1-3) induced increase in ACR. (C )
Open capillary area (an indicator of the status of the endothelium of the
glomerular capillaries) from the four groups of mice as percentage of
glomerular tuft area. (D) PAS-positive area in the kidneys (an indicator of
mesangial expansion). Nam increased the open capillary area and de-
creased the mesangial expansion. (E and F ) Light and electron micro-
graphs of illustrative glomeruli from the four groups of mice. Note the
endotheliosis and loss of fenestrae caused by Flt1(1-3), and their ame-
lioration by Nam. In A and B, numbers of mice are within the bars. In
C and D, numbers of glomeruli/number of mice are within the bars. En,
glomerular endothelium; Ep, glomerular epithelium; arrows, endothelial
fenestrae. Data are mean ± SEM. Multiple comparisons, A–D, used the
Tukey–Kramer test.
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Fig. 2. Nicotinamide delays miscarriages and prevents fetal growth restriction
induced by Flt1(1-3) and decreases expression of Flt1 in placentas. (A) Con-
tinuing pregnancies in outbred ICR mice receiving rAdV Flt1(1-3) (1 × 109 pfu)
at 8.5 dpc with or without Nam daily by gavage beginning on 6.5 dpc. We
determined the termination of pregnancy by a decrease in BW. Miscarriages
involve almost all of the fetuses. We never encountered miscarriages in which
only a few fetuses were involved. Parentheses show numbers of pregnancies.
Nam delayed the miscarriages (Mantel–Cox log-rank test). (B) Maternal plasma
sFLT1 concentrations versus delivery day of ICR mice receiving 6 × 108 pfu of
rAdV Flt1(1-3) at 14.5 dpc with (red open circles) or without Nam by gavage
beginning on 12.5 dpc (black filled circles). Dams given Nam had higher sFLT1
levels than dams which delivered their pups on the same day but were not
given Nam (by ANCOVA). (C) Fetal weights at 18.5 dpc from dams receiving
6 × 108 pfu of rAdV GFP alone at 14.5 dpc (Ctrl), or rAdV GFP at 14.5 dpc and
Nam beginning at 12.5 dpc (Nam), or 6 × 108 pfu of Flt1(1-3) virus at 14.5 dpc
[Flt1(1-3)], or dams receiving both virus and Nam [Flt1(1-3) + Nam]. Fetal weights
were normalized by Nam. The numbers of fetuses/number of pregnancies are
shown in parentheses. (D) mRNA expression (relative to expression in the pla-
centas from control mice) of Flt1in placentas at 18.5 dpc from mice that received
rAdV Flt1(1-3) (6 × 108 pfu) at 14.5 dpc with or without Nam starting at 12.5 dpc.
Nam decreased Flt1 expression. Data are means ± SEM. Multiple comparisons,
C and D, used the Tukey–Kramer test.
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our finding that plasma levels of sFLT1, VEGF, and placental
growth factor (PGF) in pregnant mice at 18.5 dpc were not al-
tered by nicotinamide (Fig. S2).
Nicotinamide Prolongs Pregnancies and Lessens FGR in PE Caused by
Increased Maternal Production of Flt1(1-3). Any treatment in a
pregnant woman with severe early-onset PE that postpones the
need to induce labor to save her life or benefit her baby is
beneficial because it decreases the prematurity of the neonate.
We therefore tested whether nicotinamide can prolong preg-
nancy in mice with increased Flt1(1-3) expression induced at
different times during pregnancy. Our first test was with 109 pfu
of rAdV Flt1(1-3) administered at 8.5 dpc to pregnant mice that
were receiving or not receiving nicotinamide daily by gavage
beginning at 6.5 dpc. This test allowed us to assess the effects of
nicotinamide under conditions of exposure to high Flt1(1-3)
relatively early in pregnancy. The results show that nicotinamide
had highly significant effects in prolonging pregnancies under
these circumstances, although none of the pregnancies went to
term (Fig. 2A). Interestingly, the plasma sFLT1 levels in mice
given nicotinamide and Flt1(1-3) virus were higher than in mice
given the virus alone (Fig. 2B); nevertheless, mice exposed to
increased levels of sFLT1 maintain their pregnancies longer if
given nicotinamide.
To have pregnancies in which the effects of nicotinamide on
PE-induced FGR could be measured, we reduced the dose of
Flt1(1-3) virus to 6 × 108 pfu, administered it at a later time in
the pregnancy (14.5 dpc) when placental development is more
complete, and harvested the fetuses at 18.5 dpc. We found that
Flt1(1-3) virus administered at this later stage of pregnancy with
or without nicotinamide did not significantly affect maternal
weight gain, uterine weights at the time of harvest, or number of
fetuses per pregnancy, indicating that Flt1(1-3) has few harmful
events once the placenta is fully matured (Table S1). Never-
theless, fetal weights at 18.5 dpc were decreased by the Flt1(1-3)
virus (Fig. 2C), and nicotinamide protected the fetuses from this
growth restriction (Fig. 2C). Placental expression of Flt1 was
increased by maternal Flt1(1-3) (Fig. 2D) and was corrected by
nicotinamide (Fig. 2D), suggesting that nicotinamide alleviated
placental ischemia. We conclude that nicotinamide significantly
lessens the FGR that occurs in the fetuses of dams exposed
to Flt1(1-3).
Nicotinamide Prevents the Hypertension, Albuminuria, and Renal
Abnormalities in PE Caused by Absence of ASB4. A substantial
body of data indicates that PE in humans is a consequence of
placental abnormalities caused by inadequate invasion of the
maternal uterine endometrium by embryonic cytotrophoblasts
(12, 13). In mice, giant trophoblast cells (GTCs), differentiated
from trophoblast stem cells, mediate the early stages of this in-
vasion, by producing matrix metalloproteinases (14, 15). This
differentiation pathway is compromised in mice that genetically
lack ASB4 (Ankiryn-repeat-and-SOCS-box-containing-protein
4), and pregnant Asb4−/− mice have shallow placentas and de-
velop a PE-like condition (14). Asb4−/− mice therefore provide a
model of PE in which the condition is initiated by inadequate
placentation, which contrasts with the Flt1(1-3) model in which
the condition is initiated by maternal overproduction of anti-
angiogenic factors. ASB4 ubiquitinates inhibitor of DNA binding
2 (ID2) and causes it to be degraded in the proteasome. In the
absence of ASB4, ID2 inhibition persists, and the differentiation
of trophoblast stem cells into GTCs is impaired. Abnormal
persistence of ID2 expression is also observed in placental bi-
opsies from human PE patients (16), further exemplifying the
similarities between the human condition and the Asb4−/− mouse
model. Many Asb4−/− embryos die and are resorbed, so that
Asb4−/− dams produce fewer pups and, like human PE patients,
they exhibit hypertension and proteinuria (14).
Using this second model of PE, we first assessed the effects of
nicotinamide on the maternal hypertension and albuminuria that
develop in the Asb4−/− mice mated with the Asb4−/− males, and
given or not given nicotinamide in their drinking water starting at
the beginning of the pregnancy (0.5 dpc). Tail cuff-measured
SBP of both groups was close to normal in the first week of
pregnancy, but had increased by about 25 mmHg in the un-
treated Asb4−/− mice by the third week (Fig. 3A). Nicotinamide
prevented this increase (Fig. 3A). By the third week of preg-
nancy, the untreated Asb4−/− dams had developed albumin-
uria (Fig. 3B), which was also completely prevented by the
dietary nicotinamide (Fig. 3B). Absence of ASB4 also resulted
in endotheliosis as judged by a decrease in the open capillary areas
of the renal glomeruli of the dams (Fig. 3C) and in mesangial
expansion as judged by an increase in PAS-positive area in the
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Fig. 3. Nicotinamide prevents the increases in BP and urinary albumin
excretion, and ameliorates glomerular pathology in pregnant mice lacking
ASB4. Asb4−/− females mated with Asb4−/− males and WT females mated
with WT males were randomly enrolled into two groups given or not given
0.3% Nam in their drinking water starting at 0.5 dpc. (A) Average SBP during
the first week and third week of pregnancy of Asb4−/− mice with or without
Nam. Nam prevented the increase in SBP caused by absence of ASB4. (B) Average
ACR of urine samples from virgin Asb4−/− females and from pregnant Asb4−/−
females during the third week of pregnancy with or without Nam. Nam
prevented the albuminuria caused by absence of ASB4. (C) Open glomerular
capillary area and (D) PAS-positive area in the kidneys of 18.5 dpc pregnant mice
as percentage of glomerular tuft area. Nam corrected the loss of open capillaries
and reduced mesangial expansion caused by absence of ASB4. (E and F) Light
and electron micrographs of illustrative glomeruli from the four groups of mice.
Mesangial interposition (black arrow) and flocculent subendothelial material
(white arrow) were apparent in the capillary loop from the Asb4−/− mouse not
receiving Nam. These indicators of mesangial expansion and endotheliosis were
not seen in any of 130 capillary loops from two Asb4−/− pregnant mice receiving
Nam but were seen in 12 of 63 capillary loops from two Asb4−/− pregnant mice
not receiving Nam (P = 0.0098; Fisher’s exact test). In A and B, the blue lines
indicate normal values inWT pregnant mice (14). In C and D, the numbers within
the bars show numbers of glomeruli examined (three mice in each group).
Multiple comparisons, A–D, used the Tukey–Kramer test.
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same glomeruli (Fig. 3D). Nicotinamide prevented the endothe-
liosis, as judged by normalization of the open capillary area
(Fig. 3C) and prevented the mesangial expansion, as judged
by normalization of the PAS-positive area (Fig. 3D). The
beneficial effects of nicotinamide in protecting the kidneys of
the pregnant mice from the deleterious effects of absence of
ASB4 are illustrated by the light and electron micrographs
shown in Fig. 3 E and F. These beneficial effects of nicotin-
amide in the pregnant Asb4−/− mice, like those in the mice
receiving Flt1(1-3) virus, were seen even though plasma levels
of sFLT1 and VEGF were not altered by the nicotinamide
(Fig. S3).
Nicotinamide Prolongs Pregnancies and Prevents Loss of Embryos in
PE Caused by Absence of ASB4. Fetal distress is as likely as ma-
ternal hypertension to be the reason for induction of delivery in
patients with severe early onset PE, but overall results in pro-
longing pregnancies to improve fetal well-being have been
disappointing (17, 18). Accordingly, we tested whether nico-
tinamide can prolong and improve the outcome of pregnancies
in the Asb4−/− mice. The results show that Asb4−/− mice not
given nicotinamide delivered prematurely at 19.5 dpc, whereas
their littermates given nicotinamide in the drinking water
throughout pregnancy delivered their pups at 20.5 dpc, which is
close to the normal time for WT mice (Fig. 4A). The beneficial
effects of nicotinamide were also apparent in dams at 18.5 dpc.
Thus, Asb4−/− dams have about half the number of live fetuses at
18.5 dpc than WT dams (Fig. 4B), and nicotinamide throughout
the pregnancy overcomes this deficiency (Fig. 4B). In contrast,
the numbers of embryonic implants (dead + alive) in the Asb4−/−
mutant mice did not differ from that in WT mice (Fig. 4C), and
nicotinamide had no effect (Fig. 4C). However, the proportion
of living embryos changed with developmental stage. Thus,
using the criteria illustrated in Fig. 4D to determine whether
an embryo or fetus is alive or dead, we found that the pro-
portion of live embryos at 11.5 dpc and earlier was not affected
by genotype or by feeding nicotinamide (Fig. 4E). However, by
12.5 dpc, the proportion of live embryos was less than 40% in
the dams lacking ASB4 (Fig. 4F), and nicotinamide increased
this proportion to ∼80% (Fig. 4F). Together these results dem-
onstrate that the deleterious event(s) causing loss of Asb4−/−
embryos and the beneficial effects of nicotinamide both occur
before 12.5 dpc.
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Fig. 4. Nicotinamide prolongs the pregnancy and reduces embryonic
deaths in pregnant mice lacking ASB4. (A) Continuing pregnancies in mice
lacking ASB4 with or without 0.3% Nam in their drinking water starting at
0.5 dpc; parentheses show the numbers of pregnancies studied. Nam pro-
longed the pregnancies of the Asb4−/− dams (Mantel–Cox log-rank test).
(B) Average number of live fetuses per pregnancy at 18.5 dpc in WT × WT
and Asb4−/− × Asb4−/− matings with or without Nam. The number of sur-
viving fetuses in the Asb4−/− pregnancies was normalized when the dams
received Nam. (C) A compilation of average number of implants (dead +
alive) in the four groups of mice at 10.5–12.5 dpc. The number of implants
is not affected by genotype or nicotinamide. (D) Images of uteri harvested
at 12.5 dpc, when dead embryos have not yet been resorbed. The chocolate
brown color of methemoglobin vs. the red color of oxyhemoglobin enables
determination of whether a fetus is alive or dead. (E) A compilation of
average proportion of live embryos at 9.5, 10.5, and 11.5 dpc in WT and
Asb4−/− matings with or without Nam. Very few embryos are dead. (F )
Average proportion of live embryos at 12.5 dpc in WT and Asb4−/− matings
with or without Nam. The proportion of living embryos in the Asb4−/−
pregnancies not receiving Nam is now only about 40% normal; Nam more
than doubles this proportion. Multiple comparisons used the Tukey–
Kramer test. Error bars are SEM.
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Fig. 5. Roles of ADPRC and its inhibitors on hypertension induced by
Flt1(1-3). (A) Tail-cuff BP immediately before (open black bar) and 5 d (filled
black bar) after administering rAdV Flt1(1-3) (1 × 109 pfu) to female
nonpregnant WT mice and to mice lacking CD38, Cd38−/−(open and filled
yellow bars), which codes for the major form of ADPRC. Absence of CD38
prevents the Flt1(1-3)–induced hypertension. (B) Telemetrically mea-
sured SBP of nonpregnant CD38 WT (Cd38+/+) mice and Cd38−/− mice
that had been given rAdV Flt1(1-3) (pre) and were then treated with
nicotinamide by gavage (Nam). Absence of CD38 made the SBP insensi-
tive to virus (pre; filled yellow bar) or virus plus nicotinamide (Nam;
cross-hatched yellow bar). (C ) Telemetrically measured SBPs of a female
nonpregnant CD38 WT mouse and a mouse lacking CD38 given Nam by
gavage 5 d after receiving 1 × 109 pfu of Flt1(1-3) virus. The SBP of the
CD38 WT mice receiving the Flt1(1-3) virus rapidly decreased from ∼140
to ∼100 mmHg followed by a rise to ∼110 mmHg. Nam had no demon-
strable effect on the near normal SBP of the Flt1(1-3)–treated mutant
mouse lacking CD38. (D) SBP of a WT female treated intraperitoneally
with DAB, a specific inhibitor of ADPRC. The SBP was decreased by DAB,
but the effect did not persist. (E ) A comparison of the time courses of the
effects of Nam and DAB on the SBP of mice that had already been given
Flt1(1-3) virus, averaged from tests with 10 and 6 mice each group. The
BP-lowering effect of Nam increases over the 60-min test period,
whereas that of DAB decreases.
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Mechanisms Underlying the Effects of Nicotinamide on BP. Nicotin-
amide is an inhibitor of ADP ribosyl cyclase (ADPRC) (5) and
is an effective vasodilator of vessels already constricted by
EDN1 (5). Because EDN1 increases cytosolic calcium by activating
ADPRC (2, 3, 19), we used mice lacking Cd38 (which codes for
the major form of ADPRC) to investigate the mechanism of
action of nicotinamide in Flt1(1-3)–treated mice. In non-
pregnant CD38 WT females, the Flt1(1-3) virus increased tail
cuff BP by ∼20 mmHg (Fig. 5A). However, in the CD38-null
mice, Flt1(1-3) expression no longer increased BP (Fig. 5A).
Telemetrically measured SBP of mice lacking CD38 was likewise
not increased by the Flt1(1-3) virus, and nicotinamide no longer
had any effect (Fig. 5B).
The time course of the effects of nicotinamide on the high SBP
of mice that received the Flt1(1-3) virus was evaluated tele-
metrically. A typical result shows that the SBP rapidly decreased
from ∼140 to ∼95 mmHg immediately after administering
nicotinamide at the usual dose of 500 mg/kg per day by gavage
as a bolus and that this decrease was followed shortly by a rise
of ∼15 to ∼110 mmHg, a level that persisted for at least 1 h
(Fig. 5C). Nicotinamide had much less effect on the already
near normal SBP of the Flt1(1-3)–treated mutant mice lacking
CD38 (Fig. 5C). This type of experiment, which was repeated
at least six times, shows that the increase in BP caused by
Flt1(1-3) and the effects of nicotinamide on BP are largely
dependent on the presence of CD38. The results also indicate
that, when nicotinamide is administered as a bolus by gavage
to Flt1(1-3) virus-treated mice, BP decreases in two phases:
one that persists for a few minutes and a second that persists
for at least 1 h.
Comparable experiments in which DAB (2,2’-dihydrox-
yazobenzene, a specific inhibitor of ADPRC) was administered by
gavage show that it also decreases Flt1(1-3)–induced hypertension
(Fig. 5D). However, although the effects of nicotinamide increase
with time, the effects of DAB decrease with time (Fig. 5E). Sur-
prisingly, the effects on SBP of giving nicotinamide or DAB by
gavage to mice not receiving the Flt1(1-3) virus (Fig. S4) were al-
most identical in their time course and magnitude to those observed
in mice that received the virus, showing that nicotinamide is a
hypotensive agent when administered as a bolus by gavage.
However, when mice not receiving the Flt1(1-3) virus were given
the same total dose of nicotinamide over the course of a day via
the drinking water, BP was not affected (data not shown).
Mechanisms Underlying the Effects of Nicotinamide on FGR and
Pregnancy Outcome. Nicotinamide is converted in two enzymatic
steps into NAD+ via the nucleotide salvage pathway, and even in
the absence of deliberate dietary supplementation is considered
to be the main source of NAD+ in mammals (20). During oxi-
dative metabolism, NAD+ is converted via the tricarboxylic acid
(TCA) cycle into NADH, which provides electrons used in the
electron transfer system to generate ATP. During glycolysis,
NAD+ is an essential participant in the reactions that lead to
the generation of ATP. NAD+ is also a substrate for sirtuin 1
(SIRT1), a deacetylase that modulates cellular responses to
hypoxia by deacetylating and inactivating the hypoxia inducible
transcription factor 1 α (HIF1A) (21), which mediates physio-
logical and pathophysiological responses to hypoxia and controls
many of the metabolic activities that generate ATP (22).
Accordingly, we expected that nicotinamide would improve
the status of hypoxic embryos and fetuses by its metabolic ef-
fects independently of its effects in decreasing the blood pres-
sure and endotheliosis of their mothers. To test whether this
expectation is met, we harvested brains from 18.5-dpc fetuses,
measured the expression of Hif1a, and performed an extensive
metabolomic analysis of brains. The results showed that
administration of nicotinamide to the mothers completely pre-
vented the increased expression levels of Hif1a caused in the
fetal brain by Flt1(1-3) (Fig. 6A). Fetal brain content of nico-
tinamide was increased by administration of nicotinamide to the
mothers (Fig. 6B), as was the brain content of NAD+ (Fig. 6C).
The combined result of these effects is that nicotinamide
completely averts the decrease in ATP content that occurs in
the brains of the fetuses of Flt1(1-3)–expressing dams (Fig.
6D), thereby preventing the FGR. More details of the metab-
olomics analysis are presented in Fig. S5, which shows that the
increased production of ATP in the fetuses of mothers re-
ceiving nicotinamide was due to enhanced glycolysis and TCA
cycling caused by increases in NAD pools.
Comparable effects of nicotinamide are demonstrable in our
second model of PE. Thus, administration of nicotinamide to the
mothers completely prevented the increased expression levels of
Hif1a caused in 11.5-dpc embryos of ASB4-null mice (Fig. 6E).
Fetal content of nicotinamide was increased by administration
of nicotinamide to the mothers (Fig. 6F), as was the content of
NAD+ (Fig. 6G). Absence of ASB4 significantly decreases the
ATP content of the 11.5-dpc fetuses of ASB4-null females
mated with ASB4-null males (Fig. 6H), and 0.3% nicotinamide
in their drinking water throughout pregnancy completely pre-
vented this decrease (Fig. 6H).
Mechanisms Underlying the Effects of Nicotinamide on Pregnancy
Outcomes in ASB4-Deficient Mice. The importance of ubiquitin li-
gase ASB4 in facilitating the steps leading from trophoblast
precursor cells to GTCs is well documented (14), as is the role of
GTCs in the production of matrix metalloproteinases (15) that
participate in the degradation of the interstitial matrix of the
maternal endometrium, which occurs during implantation. Lack
of ASB4 impairs the production of GTCs, leading to shallow
placentation (14), which in human PE is associated with fetal
hypoxia and increased oxidative stress (23, 24). However, our
observations suggest that absence of ASB4 in pregnant mice has
two outcomes: either the embryo dies or it survives and subse-
quent growth is sufficient that the fetus is not growth retarded.
Thus, although the number of fetuses surviving to term is greatly
decreased when the mother is ASB4 null and is much improved
when she is given nicotinamide, none of the surviving fetuses of
ASB4-null mothers are growth retarded at 18.5 dpc whether or
not the mothers received nicotinamide.
A C D
E G H
0
1
2
3
4
5
12 9 8 9H
if1
a
(A
.U
.) p=0.003
p=0.60
p=0.85
p=0.011
8 9H
if1
a
(A
.U
.)
0N
A
D
+
(
g/
g)
100
200
p=0.78
p=0.023
p=0.23
p=0.003
12 9 108N
am
 (
g/
g)
300
400
0
5
10
15
20 p=0.99
p=0.0027
p=0.87
p=0.0025
912
N
am
 (
g/
g)
12
p=0.53
p<0.0001 p=0.39
p=0.0003
0
10
20
30
11 7 9 N
A
D
+
(
g/
g)
p=0.12
p=0.0004 p=0.21
p=0.0001
11
0
100
200
116 811
B
F
AT
P 
(%
 c
on
tro
l)
p=0.049
p=0.34 p=0.60
p=0.026
0
50
100
12 12 10 10
150
AT
P 
(%
 W
T)
p=0.0025
p=0.37 p=0.89
p=0.044
0
50
100
150
10 8 10 90
1
11 8 10 10
p=0.036p=0.0092
p=0.98
p=0.83
10
Fig. 6. Metabolic effects of nicotinamide. (A–D) Fetal brains at 18.5 dpc.
Pregnant mice were given 6 × 108 pfu of rAdV GFP (control) or Flt1(1-3) virus
at 14.5 dpc with or without nicotinamide (Nam) by gavage starting at
12.5 dpc. At 18.5 dpc, the mice were killed, and the brains of their fetuses
were assayed for hypoxia inducible factor (Hif1a) mRNA expression and for
content of several other indicators of metabolic status: (A) Hif1a mRNA
expression relative to control. (B–D) Content of Nam, NAD+, and ATP.
Administration of Nam decreased Hif1a mRNA expression in the brain, in-
creased brain content of Nam, and brain content of NAD+. Nam completely
prevented the decrease in ATP content of the brain caused by Flt1(1-3). (E–H)
Fetuses at 11.5 dpc. Asb4 WT and Asb4−/− females were mated with Asb4 WT
and Asb4−/− males, respectively, and were given or not given 0.3% Nam in
their drinking water beginning at 0.5 dpc and the parameters of the whole
fetuses were determined at 11.5 dpc. Absence of ASB4 increased Hif1a and
decreased ATP. Nam completely prevented the effect of ASB4 absence on ATP
content of the embryos.
13454 | www.pnas.org/cgi/doi/10.1073/pnas.1614947113 Li et al.
Nicotinamide, acting via nucleotide salvage pathway, benefits
ASB4-null mothers and their progeny, by improving the metabolic
status of the hypoxic embryos in the same way that it benefits the
progeny of pregnant mice with Flt1(1-3)-induced PE. This effect is
demonstrable in 11.5 dpc embryos in which the decrease in ATP
levels caused by maternal absence of ASB4 is prevented by nico-
tinamide in the drinking water (Fig. 6H). Accordingly, it is ap-
parent that nicotinamide has beneficial metabolic effects which
can improve the status of hypoxic embryos independently of its
potential effects in improving implantation.
Nicotinamide Acts via Two Synergistic Pathways. Fig. S6 presents
diagrammatically an overview of the pathways via which nico-
tinamide may benefit both mothers and pups in our two con-
trasting mouse models of PE. Nicotinamide inhibits ADPR
cyclase, relaxes blood vessels constricted by sFLT1 (2, 3), and
improves the condition of the endothelium, thereby correcting
the hypertension and the albuminuria caused in the mothers by
PE. At the same time, acting through the NAD+ salvage pathway,
it improves the metabolic state of hypoxic embryos, normalizes
their production of ATP, and prevents FGR. Nicotinamide
probably ameliorates the consequences of PE-associated ische-
mia in the same way that it protects the heart from ischemic
reperfusion injury (25).
Concluding Remarks
Our experiments show that oral nicotinamide, a naturally oc-
curring and well-tolerated form of vitamin B3, alleviates the
maternal problems and improves the status of the offspring in
two contrasting mouse models of PE: a model in which Flt1(1-3)
is produced in the mother’s liver and a model in which placen-
tation is compromised by absence of ASB4 in the embryos and
mothers. The first model reproduces the consequences of having
a high plasma level of sFLT1, which is an invariable feature of
PE in humans. The second model reproduces the effects of
impaired placentation, which is also observed in human pa-
tients. The clear benefits of nicotinamide in the two models
suggest that it should be evaluated for use in human PE. Be-
cause there are only anecdotal reports that it is safe during
pregnancy, safety tests have been initiated in pregnant women
at 24- to 36-wk gestation with the diagnosis of hypertensive
complications of pregnancy (#NCT02213094).
Materials and Methods
All animal experiments were conducted in accordance with the guidelines at
University of North Carolina and at Tohoku University. We expressed Flt1(1-3) (7,
26) using adenovirus in nonpregnant female C57BL/6J WT mice and pregnant
ICR mice, given or not given nicotinamide (Nam) daily by gavage. We also used
Asb4−/− females. Maternal phenotype, maintenance of pregnancy, and embry-
onal phenotypewere analyzed as described in detail in SI Materials andMethods
and Table S2.
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